Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about NAFLD: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No summary available yet.
No AI portrait yet
| Associated Genes | AMPK, BECN1, FOXO1, KDM6B, LAMP2, NLRP3, NUP85, PPAR |
| Therapeutic Agents | gastrodin, hesperetin, Hesperetin, Postbiotics, Pterostilbene, SCHISANHENOL |
| KG Connections | 205 knowledge graph edges |
| Databases | OMIMOrphanetClinicalTrialsPubMed |
graph TD
NAFLD["NAFLD"] -->|"increases risk"| Atherosclerotic_Cardiovascular["Atherosclerotic Cardiovascular Disease"]
style Atherosclerotic_Cardiovascular fill:#1a2a3a,stroke:#ef5350,stroke-width:1px,color:#fff
NAFLD["NAFLD"] -->|"associated"| METABOLIC_SYNDROME["METABOLIC_SYNDROME"]
style METABOLIC_SYNDROME fill:#1a2a3a,stroke:#ef5350,stroke-width:1px,color:#fff
NAFLD["NAFLD"] -->|"contributes to"| STEATOHEPATITIS["STEATOHEPATITIS"]
style STEATOHEPATITIS fill:#1a2a3a,stroke:#ef5350,stroke-width:1px,color:#fff
NAFLD["NAFLD"] -->|"activates"| CIRRHOSIS["CIRRHOSIS"]
style CIRRHOSIS fill:#1a2a3a,stroke:#ef5350,stroke-width:1px,color:#fff
NAFLD["NAFLD"] -->|"implicated in"| OXIDATIVE_STRESS["OXIDATIVE STRESS"]
style OXIDATIVE_STRESS fill:#1a2a3a,stroke:#ffd54f,stroke-width:1px,color:#fff
NAFLD["NAFLD"] -->|"associated"| RNA_SPLICING["RNA SPLICING"]
style RNA_SPLICING fill:#1a2a3a,stroke:#ffd54f,stroke-width:1px,color:#fff
NAFLD["NAFLD"] -.->|"inhibits"| OXIDATIVE_PHOSPHORYLATION["OXIDATIVE PHOSPHORYLATION"]
style OXIDATIVE_PHOSPHORYLATION fill:#1a2a3a,stroke:#ffd54f,stroke-width:1px,color:#fff
hesperetin["hesperetin"] -->|"treats"| NAFLD["NAFLD"]
style hesperetin fill:#1a2a3a,stroke:#81c784,stroke-width:1px,color:#fff
NUP85["NUP85"] -->|"associated"| NAFLD["NAFLD"]
style NUP85 fill:#1a2a3a,stroke:#4fc3f7,stroke-width:1px,color:#fff
Triglyceride_Accumulation["Triglyceride Accumulation"] -->|"causes"| NAFLD["NAFLD"]
style Triglyceride_Accumulation fill:#1a2a3a,stroke:#ffd54f,stroke-width:1px,color:#fff
gastrodin["gastrodin"] -->|"treats"| NAFLD["NAFLD"]
style gastrodin fill:#1a2a3a,stroke:#81c784,stroke-width:1px,color:#fff
AMPK["AMPK"] -->|"protects against"| NAFLD["NAFLD"]
style AMPK fill:#1a2a3a,stroke:#4fc3f7,stroke-width:1px,color:#fff
style NAFLD fill:#ef5350,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0,font-weight:bold| Target | Relation | Type | Str |
|---|---|---|---|
| Fatty Liver | associated_with | disease | 1.00 |
| Liver Cirrhosis | contributes_to | disease | 0.95 |
| Hepatocellular Carcinoma | contributes_to | disease | 0.95 |
| Inflammation | therapeutic_target | disease | 0.85 |
| Chronic Liver Disease | contributes_to | disease | 0.85 |
| Fatty Liver | therapeutic_target | disease | 0.85 |
| Fatty Liver | treats | disease | 0.85 |
| Atherosclerotic Cardiovascular Disease | increases_risk | disease | 0.80 |
| Mtor | activates | pathway | 0.80 |
| Lipid Metabolism | regulates | pathway | 0.80 |
| Oxidative Stress | activates | pathway | 0.80 |
| Inflammation | associated_with | disease | 0.75 |
| METABOLIC_SYNDROME | associated_with | disease | 0.72 |
| Autophagy | regulates | pathway | 0.70 |
| Apoptosis | associated_with | pathway | 0.70 |
| Mtor | therapeutic_target | pathway | 0.70 |
| Lipid Metabolism | activates | pathway | 0.70 |
| Er Stress | associated_with | pathway | 0.70 |
| Hepatitis | associated_with | disease | 0.65 |
| EGF | regulates | gene | 0.65 |
| Fatty Liver | activates | disease | 0.65 |
| Insulin Resistance | therapeutic_target | disease | 0.65 |
| Obesity | therapeutic_target | disease | 0.65 |
| AMPK | phosphorylates | gene | 0.65 |
| AMPK | targets | gene | 0.65 |
| Fatty Liver | causes | disease | 0.65 |
| Fatty Liver | biomarker_for | disease | 0.65 |
| Als | activates | disease | 0.65 |
| Hepatitis | treats | disease | 0.65 |
| STEATOHEPATITIS | contributes_to | disease | 0.64 |
| Foxo Signaling | activates | pathway | 0.60 |
| Jak-Stat | activates | pathway | 0.60 |
| Microbiota | activates | pathway | 0.60 |
| Proteasome | regulates | pathway | 0.60 |
| Chaperone | therapeutic_target | pathway | 0.60 |
| Lipid Metabolism | causes | pathway | 0.60 |
| Immune Response | therapeutic_target | pathway | 0.60 |
| Unfolded Protein Response | therapeutic_target | pathway | 0.60 |
| Ferroptosis | therapeutic_target | pathway | 0.60 |
| Complement | therapeutic_target | pathway | 0.60 |
| Autophagy | associated_with | pathway | 0.60 |
| Cholesterol | inhibits | pathway | 0.60 |
| Nf-Κb | regulates | pathway | 0.60 |
| Inflammasome | activates | pathway | 0.60 |
| Autophagy | activates | pathway | 0.60 |
| Inflammasome | regulates | pathway | 0.60 |
| Senescence | regulates | pathway | 0.60 |
| Microbiota | regulates | pathway | 0.60 |
| Lipid Metabolism | associated_with | pathway | 0.60 |
| Glycolysis | activates | pathway | 0.60 |
| Source | Relation | Type | Str |
|---|---|---|---|
| INFLAMMATION | therapeutic_target | gene | 0.95 |
| NUP85 | associated_with | gene | 0.95 |
| Als | therapeutic_target | disease | 0.95 |
| Hfd | causes | phenotype | 0.95 |
| Pterostilbene | treats | compound | 0.95 |
| hesperetin | treats | drug | 0.90 |
| Autophagy | involved_in | process | 0.90 |
| DRAK2 | aggravates | gene | 0.90 |
| Triglyceride Accumulation | causes | phenotype | 0.90 |
| AKT | activates | gene | 0.85 |
| OXIDATIVE STRESS | activates | gene | 0.85 |
| PI3K | activates | gene | 0.85 |
| INFLAMMATION | associated_with | gene | 0.85 |
| MTOR | activates | gene | 0.85 |
| gastrodin | treats | drug | 0.85 |
| Lipid Droplets | associated_with | phenotype | 0.85 |
| AMPK | protects_against | protein | 0.80 |
| Postbiotics | treats | compound | 0.80 |
| AMPK | therapeutic_target | pathway | 0.80 |
| PI3K/AKT Signaling Pathway | involved_in | pathway | 0.80 |
| Mitochondrial Impairment | contributes_to | phenotype | 0.80 |
| Fibrosis | therapeutic_target | disease | 0.75 |
| LDL | activates | gene | 0.75 |
| Cancer | associated_with | disease | 0.75 |
| INSULIN RESISTANCE | therapeutic_target | gene | 0.75 |
| APOPTOSIS | associated_with | gene | 0.75 |
| NF-κB | therapeutic_target | pathway | 0.75 |
| AUTOPHAGY | regulates | gene | 0.75 |
| GENES | activates | gene | 0.75 |
| MTOR | therapeutic_target | gene | 0.75 |
| CANCER | associated_with | gene | 0.75 |
| Hepatocellular Carcinoma | therapeutic_target | disease | 0.75 |
| Carcinoma | therapeutic_target | disease | 0.75 |
| MTORC1 | therapeutic_target | gene | 0.75 |
| DIABETES MELLITUS | causes | gene | 0.75 |
| LIPOPHAGY | therapeutic_target | gene | 0.75 |
| NRF2 | activates | gene | 0.75 |
| AUTOPHAGY | associated_with | pathway | 0.72 |
| SCHISANHENOL | treats | drug | 0.72 |
| Hesperetin | treats | drug | 0.70 |
| OXIDATIVE STRESS | regulates | gene | 0.65 |
| CYP3A4 | associated_with | gene | 0.65 |
| IL-6 | regulates | gene | 0.65 |
| TNF-Α | regulates | gene | 0.65 |
| Metabolic Syndrome | contributes_to | disease | 0.65 |
| VEGFB | activates | gene | 0.65 |
| INSULIN RESISTANCE | regulates | gene | 0.65 |
| IRS1 | activates | gene | 0.65 |
| Als | regulates | disease | 0.65 |
| PPAR | regulates | gene | 0.65 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| No targeting hypotheses | |||
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| No experiments found | |||||||
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| No papers found | ||||
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning NAFLD in their description or question text
No additional research found